IDEXX Laboratories Inc

IDEXX Laboratories Inc(IDXX)股票分析

$570.210

+9.979 (+1.75%)收盤時

Loading chart…
最高
571.750
開盤
564.230
成交量加權均價
566.63
成交量
528.14K
市值
40.79B
最低
557.940
成交金額
299.26M
企業價值/稅息折舊攤銷前利潤(TTM)
23.31

IDEXX Laboratories, Inc. develops, manufactures, and distributes products and provides services primarily for the companion animal veterinary; livestock, poultry and dairy; and water testing industries. It also manufactures and sells human medical point-of-care diagnostic products. Its products and services include point-of-care veterinary diagnostic products, comprised of instruments, consumables, and rapid assay test kits. It also includes veterinary reference laboratory diagnostic and consulting services. It offers practice management systems, software and diagnostic imaging systems and services used by veterinarians. It also offers health monitoring, biological materials testing, laboratory diagnostic instruments, and services used by the biomedical research community. The Company provides diagnostic and health-monitoring products for livestock, poultry, and dairy; and products that test water for certain microbiological contaminants.

AI 分析 of IDEXX Laboratories Inc (IDXX)

買進

IDEXX Laboratories is a good buy right now at a current price of $560.38, especially considering its strong gross margin of 63.71% and a forward P/E ratio of 31.45, indicating solid earnings potential. The stock has shown resilience with a 20-day change of +7.92%, suggesting positive momentum. However, a risk to consider is the recent insider selling, where a director sold shares at $532.08, which could indicate some caution among insiders.

分析師評級(10)

上檔空間 +39.03%
買進
6 買進
3 持有
1 賣出
目前: 570.21
最低
750.00
平均
792.78
最高
850.00

KeyBanc

2026-10-12

目標價

—

Sector Weight

Barclays

2026-08-11

目標價

$710

增持

Citi

2026-08-05

目標價

$670

中性

UBS

2026-07-27

目標價

$620

中性

Stifel

2026-07-15

目標價

$564.42

買進

估值指標

IDEXX Laboratories Inc(IDXX)目前預期本益比為 31.45,5 年平均預期本益比為 45.77。

預期本益比

低估
5 年均值 P/E
45.77
目前P/E
31.45
高估
54.89
低估
36.64

預期 EV/EBITDA

低估
5 年均值 EV/EBITDA
31.89
目前EV/EBITDA
23.31
高估
37.90
低估
25.88

預期股價營收比

合理
5 年均值 P/S
10.27
目前P/S
8.68
高估
12.05
低估
8.49

Alphio AI 對 IDXX 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%IDXX

$650.45

情境價格

基

基準

基準 · 50%IDXX

$608.98

情境價格

悲

悲觀

悲觀 · 25%IDXX

$597.63

情境價格

持有 IDXX 的大戶

B

Baron Capital Group, Inc.

+ 持有IDXX

+13.36%

3個月報酬率

E

Entropy Technologies, LP

+ 持有IDXX

+8.72%

3個月報酬率

A

American Capital Management, Inc.

+ 持有IDXXMEDP

+8.15%

3個月報酬率

T

Trexquant Investment LP

+ 持有IDXX

+7.53%

3個月報酬率

J

Joel R. Mogy Investment Counsel Inc.

+ 持有IDXX

+7.45%

3個月報酬率

L

Loring, Wolcott & Coolidge Fiduciary Advisors, LLP

+ 持有IDXX

+6.95%

3個月報酬率

事件時間軸

2026-09-16 (ET)

07:30:00

IDEXX Laboratories Acquires CoVetAI to Expand Software Ecosystem

2026-08-11 (ET)

07:30:00

IDEXX Launches Catalyst proBNP Test, Enhancing Cardiac Testing Capabilities

2026-08-04 (ET)

09:00:00

IDEXX Laboratories Q2 Revenue $1.22B Beats Expectations

08:30:00

Idexx Reports Q2 EPS of $4.27, Beating Consensus of $3.93

07:00:00

2026 EPS Consensus at $14.66, Revenue View Adjusted to $4.70B-$4.745B

資訊

IDXX 常見問題 —— 由 Alphio AI 解答

IDEXX Laboratories, Inc. develops, manufactures, and distributes products and provides services primarily for the companion animal veterinary; livestock, poultry and dairy; and water testing industries. It also manufactures and sells human medical point-of-care diagnostic products. Its products and services include point-of-care veterinary diagnostic products, comprised of instruments, consumables, and rapid assay test kits. It also includes veterinary reference laboratory diagnostic and consulting services. It offers practice management systems, software and diagnostic imaging systems and services used by veterinarians. It also offers health monitoring, biological materials testing, laboratory diagnostic instruments, and services used by the biomedical research community. The Company provides diagnostic and health-monitoring products for livestock, poultry, and dairy; and products that test water for certain microbiological contaminants. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).

IDEXX Laboratories is a good buy right now at a current price of $560.38, especially considering its strong gross margin of 63.71% and a forward P/E ratio of 31.45, indicating solid earnings potential. The stock has shown resilience with a 20-day change of +7.92%, suggesting positive momentum. However, a risk to consider is the recent insider selling, where a director sold shares at $532.08, which could indicate some caution among insiders.

10 analysts cover IDXX: 6 rate it Buy, 3 Hold and 1 Sell. The average price target is 792.78.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易